Tagged epx-100

First Canadian Participant Dosed in ARGUS Trial, A Phase 2 Potentially Pivotal Study of EPX-100 Treatment of Dravet Syndrome
Press Release

First Canadian Participant Dosed in ARGUS Trial, A Phase 2 Potentially Pivotal Study of EPX-100 Treatment of Dravet Syndrome

 Read More
Health Canada Issues No Objection Letter to Initiate the ELEGANSE Trial With EPX-100 to Treat Lennox-Gastaut Syndrome
Press Release

Health Canada Issues No Objection Letter to Initiate the ELEGANSE Trial With EPX-100 to Treat Lennox-Gastaut Syndrome

 Read More
Epygenix Therapeutics Announces FDA Acceptance of IND to Initiate a Clinical Trial of EPX-100 to Treat Lennox-Gastaut Syndrome
Press Release

Epygenix Therapeutics Announces FDA Acceptance of IND to Initiate a Clinical Trial of EPX-100 to Treat Lennox-Gastaut Syndrome

 Read More
Health Canada Grants No Objection Letter to Epygenix Therapeutics to Proceed With ARGUS Trial for the Treatment of Dravet Syndrome
Press Release

Health Canada Grants No Objection Letter to Epygenix Therapeutics to Proceed With ARGUS Trial for the Treatment of Dravet Syndrome

 Read More
Epygenix Therapeutics Announces First Patient Successfully Dosed in Phase 2 Study for the Treatment of Dravet Syndrome With EPX-100
Press Release

Epygenix Therapeutics Announces First Patient Successfully Dosed in Phase 2 Study for the Treatment of Dravet Syndrome With EPX-100

 Read More
Epygenix Therapeutics Announces First Patient Enrolled in Phase 2 Study for the Treatment of Dravet Syndrome With EPX-100
Press Release

Epygenix Therapeutics Announces First Patient Enrolled in Phase 2 Study for the Treatment of Dravet Syndrome With EPX-100

 Read More
Epygenix Therapeutics Initiates Phase 2 Study for Dravet Syndrome With EPX-100
Press Release

Epygenix Therapeutics Initiates Phase 2 Study for Dravet Syndrome With EPX-100

 Read More
Epygenix Therapeutics Successfully Completes EPX-100 Phase I, Placebo-Controlled, Double-Blind, 2-Period Study and Ready to Phase 2 Studies
Press Release

Epygenix Therapeutics Successfully Completes EPX-100 Phase I, Placebo-Controlled, Double-Blind, 2-Period Study and Ready to Phase 2 Studies

 Read More
Press Release

Epygenix Therapeutics Receives IND Approval of EPX-100 for the Treatment of Dravet Syndrome

Dravet Syndrome, a catastrophic form of epilepsy, affects one in 15,700 children and adults in the United States.

Read More
Epygenix Therapeutics Submits Investigational New Drug Application for EPX-100 to the U.S. FDA for the Treatment of Patients With Dravet Syndrome
Press Release

Epygenix Therapeutics Submits Investigational New Drug Application for EPX-100 to the U.S. FDA for the Treatment of Patients With Dravet Syndrome

 Read More